Drug, across the briefings
Sorafenib across 14 cancers
Sorafenib appears in 14 of the briefings; its FDA label names 3 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Hepatocellular carcinoma | label names disease | approved on KDR | 166 | 11 |
| Kidney cancer | label names disease | approved on KDR | 75 | 1 |
| Thyroid cancer | label names disease | approved on BRAF, RET | 15 | 2 |
| Acute myeloid leukemia | approved on FLT3, KIT | 50 | 15 | |
| Cholangiocarcinoma | approved on BRAF | 6 | 0 | |
| Colorectal cancer | approved on BRAF | 18 | 0 | |
| Gastric cancer | approved on KDR | 8 | 0 | |
| Gastrointestinal stromal tumour | approved on KIT, BRAF | 2 | 1 | |
| Lung cancer | approved on BRAF, RET | 40 | 0 | |
| Melanoma | approved on BRAF, KIT | 30 | 1 | |
| Osteosarcoma | approved on KDR | 8 | 2 | |
| Small intestine cancer | approved on BRAF, KIT | — | — | |
| Soft tissue sarcoma | approved on PDGFRB | 13 | 1 | |
| Testicular cancer | approved on KIT | 1 | 0 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.